What do systematic reviews say?

Summary of findings table ‐ Ondansetron vs placebo

• Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 202 participants
  Low

Summary of findings table ‐ Ondansetron vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ondansetron vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ondansetron vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ondansetron vs placebo

It is very uncertain whether summary of findings table ‐ Ondansetron changes risk for at least one adverse event per patient compared with placebo (very low certainty).

• Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
  RR 2.54 [0.38, 16.78]
  3 studies · 174 participants
  Very low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  39 studies · 21642 participants
  Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  39 studies · 21642 participants
  Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 16065 participants
  Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 16065 participants
  Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 16065 participants
  Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 7800 participants
  Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 7800 participants
  Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 7800 participants
  Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 7800 participants
  Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  39 studies · 21642 participants
  Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  39 studies · 21642 participants
  Low